AG Mednet has announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data
AG Mednet has announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data into configurable file structures residing either locally or in any of their network shares. This functionality provides higher-quality data and less delays, making it the most efficient method to collect and transfer Holter data, spectral-domain OCT and newer modalities not yet conforming to the DICOM standard.
Now, meta-data can be assigned to non-DICOM modalities and used for configuring, on a per-study basis, structured directories with explicit hierarchies based on the acquired meta-data. This is especially important for:
“In combination with our ability to tag and deliver this data not just to DICOM repositories but also to local file systems, we’re providing cardiovascular trials, as well as projects requiring specialized non-DICOM modalities, with a way to ensure higher quality and less delays than other methods,” said Abraham Gutman, President & CEO of AG Mednet.
For more information about AG Mednet, please visit www.agmednet.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.